IP Library Granted Patent US 9,925,210
Granted Patent B2
US 9,925,210 · App. 14/614,316 · Granted Mar 27, 2018

Chitosan materials from carbonic acid solution

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,925,210
App. No.
14/614,316
Granted
Mar 27, 2018
Kind
B2
Abstract

The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid. Chitosan materials can be mixed in solution with one or more of other hydrophilic polymers to create compositional heterogeneity and pharmaceutical agents to achieve controlled release of the agent(s) from the final forms at the site of application.

Claims (12)

1. A solid or semi-solid native final form composition comprising uniformly dispersed chitosan fibers within a substantially acid salt free chitosan solubilized gel material, wherein said material is incapable of repeated solubilization in a carbonic acid aqueous solution having a pH between about 3.4 to about 7.0.

2. The composition of claim 1 , wherein the final form composition comprises one of a powder, fiber, film, matrix, sponge, implant, scaffold, filler, and hydrogel and has an acid salt content of between about 0.01% (w/w) and about 5% (w/w).

3. The composition of claim 1 , wherein the final form composition includes a controlled release pharmaceutical or active agent delivery vehicle.

4. The composition of claim 1 , wherein the final form composition is non-adhesive, remains intact upon exposure to water, saline, blood or other biological fluid, and can remain on wounds or wet tissue surfaces over four to seven days without significant change.

5. The composition of claim 1 , wherein the substantially acid salt free chitosan solubilized gel material comprises one of medium weight and low weight chitosan.

6. The composition of claim 1 , wherein the final form composition is a water insoluble freeze phase molded hydrogel.

7. The composition of claim 1 , wherein the final form composition comprises water in an amount of less than about 10% (w/w).

8. The composition of claim 7 , wherein the final form composition absorbs between about 1000% and 1600% of water based on its weight (w/w).

9. The composition of claim 1 , wherein the final form composition has a density of about 0.005 to 0.25 g/cm 3 .

10. The composition of claim 1 , wherein the final form composition has a density of about 0.12 g/cm 3 .

11. The composition of claim 1 , wherein the final form composition does not require acid salt elution.

12. The composition of claim 1 , wherein the final form composition comprises a freeze-dried sponge.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2016
From: HEMCON MEDICAL TECHNOLOGIES, INC.
To: TRICOL BIOMEDICAL, INC.
Reel/Frame 038919/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2016
From: MCCARTHY, SIMON; MCGRATH, BARBARA; KIMBALL, JESS; KUHN, SAM; STOLTEN, MICHAEL; BENNETT, AMANDA
To: HEMCON MEDICAL TECHNOLOGIES, INC.
Reel/Frame 038837/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2015
From: MCCARTHY, SIMON; MCGRATH, BARBARA; KIMBALL, JESS; KUHN, SAM; STOLTEN, MICHAEL; BENNETT, AMANDA
To: HEMCON MEDICAL TECHNOLOGIES, INC.
Reel/Frame 035265/0275 →